{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T02:38:01Z","timestamp":1793587081999,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clgc.2024.102093","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T02:33:40Z","timestamp":1712716420000},"page":"102093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["RC48-Antibody-Drug Conjugate in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study in China"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-8981","authenticated-orcid":false,"given":"Jinchao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienie","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mang","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihai","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.clgc.2024.102093_bib0001","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O'Donnell","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102093_bib0002","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/CCO.0000000000000722","article-title":"The evolving treatment landscape of advanced urothelial carcinoma","volume":"33","author":"Andreev-Drakhlin","year":"2021","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102093_bib0003","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102093_bib0004","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.clgc.2020.11.006","article-title":"The evolving landscape of antibody-drug conjugates for urothelial carcinoma","volume":"19","author":"Abel","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"10.1016\/j.clgc.2024.102093_bib0005","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clgc.2024.102093_bib0006","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2024.102093_bib27","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clgc.2024.102093_bib0007","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1093\/oncolo\/oyad070","article-title":"HER2 expression associated with clinical characteristics and prognosis of urothelial carcinoma in a Chinese population","volume":"28","author":"Zhou","year":"2023","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.clgc.2024.102093_bib0008","first-page":"699","article-title":"HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients","volume":"7","author":"Sasaki","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102093_bib0009","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1309\/41VLTFX3YPP1HF6F","article-title":"HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases","volume":"130","author":"Hansel","year":"2008","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102093_bib0010","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1016\/j.clgc.2019.12.003","article-title":"HER2 status in molecular subtypes of urothelial carcinoma of the renal pelvis and ureter","volume":"18","author":"Yorozu","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2024.102093_bib0011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"31","key":"10.1016\/j.clgc.2024.102093_bib0012","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102093_bib0013","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.clgc.2024.102093_bib0014","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2024.102093_bib0015","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00262-023-03419-1","article-title":"HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"23","key":"10.1016\/j.clgc.2024.102093_bib0016","doi-asserted-by":"crossref","first-page":"21159","DOI":"10.1002\/cam4.6680","article-title":"Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: a multicenter, retrospective clinical study","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med"},{"issue":"19","key":"10.1016\/j.clgc.2024.102093_bib0017","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.clgc.2024.102093_bib0018","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/aac2.12048","article-title":"Patterns of treatment in older patients with newly diagnosed advanced bladder cancer: a SEER dataset analysis","volume":"3","author":"Kessler","year":"2022","journal-title":"Aging Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2024.102093_bib0019","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40266-022-00933-2","article-title":"Management of advanced urothelial carcinoma in older and frail patients: have novel treatment approaches improved their care?","volume":"39","author":"Russell","year":"2022","journal-title":"Drugs Aging"},{"issue":"10064","key":"10.1016\/j.clgc.2024.102093_bib0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clgc.2024.102093_bib0021","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102093_bib0022","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.euros.2023.04.018","article-title":"Enfortumab vedotin in metastatic urothelial carcinoma: survival and safety in a European Multicenter Real-world Patient Cohort","volume":"53","author":"Zsch\u00e4bitz","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"10.1016\/j.clgc.2024.102093_bib0023","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/cncr.34057","article-title":"Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study","volume":"128","author":"Koshkin","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2024.102093_bib0024","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.urology.2015.12.007","article-title":"Front-line treatment with gemcitabine, paclitaxel, and doxorubicin for patients with unresectable or metastatic urothelial cancer and poor renal function: final results from a phase II study","volume":"89","author":"Siefker-Radtke","year":"2016","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.clgc.2024.102093_bib0025","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clgc.2023.12.001","article-title":"First-line management of metastatic urothelial cancer: current and future perspectives after the EV-302 and CheckMate-901 studies","volume":"22","author":"Fenor de la Maza","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2024.102093_bib0026","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.515","article-title":"Study RC48-C014: preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma","volume":"40","author":"Zhou","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2024.102093_bib28","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.21873\/anticanres.16594","article-title":"Efficacy and tolerability of enfortumab vedotin for metastatic urothelial carcinoma: early experience in the real world","volume":"43","author":"Minato","year":"2023","journal-title":"Anticancer Res"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T08:01:19Z","timestamp":1717660879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324000648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1558767324000648"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102093","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RC48-Antibody-Drug Conjugate in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study in China","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102093"}}